2 Palestinian Youths Hurt in Clashes With Israel

Mussa Issa Qawasma/Reuters

A Palestinian protester threw stones during clashes with Israeli soldiers on Monday in Hebron, West Bank, after a funeral for a Palestinian prisoner.

JERUSALEM — Two Palestinian teenagers were seriously injured Monday when Israeli soldiers used live ammunition to disperse a demonstration at a holy site outside Bethlehem, as clashes in the West Bank continued for a fifth day and thousands attended the burial of a 30-year-old Palestinian who died in an Israeli jail over the weekend.

The Palestinian president, Mahmoud Abbas, spoke for the first time on Monday about the prisoner, Arafat Jaradat, saying that Israel must be held responsible for his death and that its leaders were trying to foment chaos rather than work toward peace.

Other Palestinian officials have said Mr. Jaradat died because of torture during interrogation. An autopsy conducted Sunday did not immediately determine the cause of death, but an Israeli official said Monday that a report on the findings should be released by the end of the week and that the police and courts were investigating the death separately.

“Jaradat went to jail and returned back a dead body,” Mr. Abbas said Monday in Ramallah, hours before the teenagers were shot near Bethlehem. “We insist to know how this happened and who did this. We will not let them play in the lives of our sons. They are confronting children and killing them with live ammunition. We will not allow our prisoners to remain in the occupation jails all their lives for things that they did not commit.”

About 10,000 people accompanied Mr. Jaradat’s body from a hospital in Hebron to his family’s home in Sa’ir, a village nearby, and then to the cemetery. The Israeli military closed a main road for the procession, in which members of Al Aksa Martyrs Brigades, the militant wing of the Fatah party, fired guns into the air.

Israel’s prime minister, Benjamin Netanyahu, who sent a message on Sunday to the Palestinian leadership demanding that it restore calm in the West Bank, held security consultations on the matter on Monday, according to a statement from his office. Defense Minister Ehud Barak convened a special meeting on Monday with the military chief of staff and the leaders of Israel’s police force and prison service “during which possible scenarios were introduced,” according to a statement from Mr. Barak’s office, “as well as possible ways to cope with them and maintain security needs while trying to restore the calm on the ground.”

The United States Consulate in Jerusalem limited travel by government employees to the West Bank because of the demonstrations and advised all American citizens to avoid the area and “to exercise an extra measure of caution during this period.”

“The U.S. Consulate General takes this opportunity to remind U.S. citizens that demonstrations, even peaceful ones, can turn violent with little or no warning,” it said in a statement. “U.S. citizens should be aware of their surroundings at all times, and avoid large crowds.”

The Egyptian foreign minister, Mohamed Kamel Amr, called on the international community to take a firm stance against what he described as Israel’s inhumane practices against the Palestinian prisoners, according to the state newspaper, and warned that a continuation of such policies could lead to an explosion in the region.

So far, the situation seems to be on a simmer. Every day since Thursday, demonstrations have occurred in several West Bank cities and villages in which Palestinians have thrown rocks and sometimes gasoline bombs at Israeli soldiers, who generally respond with tear gas, rubber bullets and occasionally water cannons or live ammunition. Most of the demonstrations, including those in Hebron and Beituniya on Monday, have drawn crowds of a few hundred and resulted in a handful of light to moderate injuries.

But more serious clashes broke out near Rachel’s Tomb on Monday afternoon and evening. An Israeli military official who spoke on the condition of anonymity said that soldiers fired .22-caliber rounds at Palestinians who were throwing improvised grenades at worshipers near the tomb, which is next to the Aida refugee camp just outside Bethlehem.

A doctor at Beit Jala Hospital who spoke on the condition that he not be identified said a 13-year-old had been shot in a lung during that protest and was in the intensive care unit Monday night after undergoing surgery. Hours later, a 19-year-old Palestinian was shot as the demonstration raged on, the doctor said.

“He is in a dangerous situation,” the doctor said of the second patient. “Doctors are trying to save his life.”

Khaled Abu Aker contributed reporting from Ramallah, West Bank; Nayef Hashlamoun from Hebron and Sa’ir, West Bank; and Mayy El Sheikh from Cairo.

Read More..

PEOPLE Live at the Oscars - Check Out Our Staffers' Tweets!

02/25/2013 at 07:35 PM EST

The Oscars hit the Dolby Theatre in L.A. Sunday night – and PEOPLE was there!

Editor Peter Castro was on the red carpet with Modern Family's Rico Rodriquez for the live pre-show event Backstage Pass – plus we had editors at the after parties and more!

Check out our best Tweets and pics from the show:

Read More..

Wall Street trips and falls on cloudy Italian election

NEW YORK (Reuters) - Stocks on Monday suffered their biggest drop since November after a strong showing in Italian elections by groups opposed to the country's economic reforms triggered worry that Europe's debt problems could once again destabilize the global economy.

The decline marks the biggest percentage drop for the benchmark Standard & Poor's 500 Index since November7, and drove the S&P down to its lowest close since January 18. The CBOE Volatility Index <.vix> or VIX, Wall Street's favorite barometer of fear, surged 34 percent, its biggest jump since August 18, 2011.

Selling accelerated late in the trading session after the S&P 500 fell below the 1,500 level, which has acted as a significant support point. Monday marked the S&P's first close under 1,500 since February 4.

Italy's center-left coalition holds a slim lead over former Prime Minister Silvio Berlusconi's center-right bloc in the election for the lower house of parliament, three TV projections indicated. But any government must also command a majority in the Senate, a race that is decided by region.

The resulting gridlock in parliament could lead to new elections and cast into doubt Italy's ability to pay down its debt.

"Europe hasn't gone away as an issue, it is going to hang around, and it is rearing its ugly head today," said Stephen Massocca, managing director of Wedbush Morgan in San Francisco.

"If someone gets elected who is simply not going to play by the rules, what are they going to do? It puts them in a real quandary here because their financial support, their monetary support is all stipulated by the fact that these austerity programs are going to be in place."

Earlier polls pointing to a center-left victory boosted stocks in Milan and other European markets, and also helped lift the S&P 500 to a session high of 1,525.84 on optimism that Italy would continue down its austerity path.

After a strong start to the year, equities have retreated more recently. The S&P 500's slight fall last week was its first weekly drop after a seven-week string of gains.

In Monday's volatile session, banks and other financial stocks were among the worst performers on worries about the sector's exposure to Italy's massive debt. The KBW Bank Index <.bkx> fell 2.7 percent.

The CBOE Volatility Index <.vix> ended at 18.99, up 34.02 percent.

The Dow Jones industrial average <.dji> dropped 216.40 points, or 1.55 percent, to 13,784.17 at the close. The Standard & Poor's 500 Index <.spx> lost 27.75 points, or 1.83 percent, to 1,487.85. The Nasdaq Composite Index <.ixic> fell 45.57 points, or 1.44 percent, to 3,116.25.

Although the overall market lost ground on Monday, there were a few bright spots.

Barnes & Noble Inc shares shot up 11.5 percent to $15.06 after the bookseller's chairman offered to buy its declining retail business.

Amgen Inc shares climbed 3.1 percent to $89.55, after rival Affymax issued a voluntary recall of its only drug, an anemia treatment that competes with Amgen's top-selling red blood cell booster, Epogen. Affymax shares lost 85.4 percent to $2.42.

The FTSEurofirst-300 index of top European shares <.fteu3> edged up 0.04 percent and Italy's main FTSE MIB <.ftmib> ended up 0.7 percent after earlier gaining nearly 4 percent.

Political uncertainty on the home front, though, is also on Wall Street's mind.

U.S. equities will face a test with the looming debate over so-called sequestration - U.S. government budget cuts that will take effect starting on Friday if lawmakers fail to reach an agreement over spending and taxes. The White House issued warnings about the harm the cuts are likely to inflict on the economy if enacted.

"Sitting out there is the one-thousand-pound gorilla - the sequester issue - and certainly nothing is happening there," said Tim Ghriskey, chief investment officer of Solaris Group in Bedford Hills, New York.

Lowe's Companies Inc lost 4.8 percent to $35.86 after the home improvement retailer posted fourth-quarter earnings.

With 83 percent of the S&P 500 companies having reported results so far, 69 percent beat profit expectations, compared with a 62 percent average since 1994 and 65 percent over the past four quarters, according to Thomson Reuters data.

Fourth-quarter earnings for S&P 500 companies are estimated to have risen 6 percent, according to the data, above a 1.9 percent forecast at the start of the earnings season.

Volume was active with about 7.27 billion shares traded on the New York Stock Exchange, NYSE MKT and Nasdaq, above the daily average of 6.46 billion.

Declining stocks outnumbered advancing ones on both the NYSE and the Nasdaq by a ratio of about 4 to 1.

(Editing by Kenneth Barry, Nick Zieminski and Jan Paschal)

Read More..

Kerry’s Meeting With Syrian Opposition at Risk

Pool photo by Jacquelyn Martin

Secretary of State John Kerry spoke to reporters on the way to London on Sunday. Mr. Kerry has said that he has new ideas on how to force President Bashar al-Assad from power in Syria.

Mr. Kerry and foreign ministers from Europe and the Middle East are scheduled to meet in Rome on Thursday with opponents of President Bashar al-Assad of Syria, including Sheik Ahmad Moaz al-Khatib, who leads the opposition. But they are threatening to boycott the conference to protest what they see as fainthearted international support.

To try to rescue the meeting, Robert S. Ford, the American ambassador to Syria and chief envoy to the opposition, was sent to Cairo on Sunday to implore opposition leaders to attend the session in Rome.

“The Syrian opposition leadership is under severe pressure now from its membership, from the Syrian people, to get more support from the international community,” said a senior administration official who was traveling on Mr. Kerry’s plane. “And in that context, there’s quite a bit of internal discussion about the value of going in international conferences.”

The issue upset the first day of a carefully choreographed trip that is intended to introduce Mr. Kerry as the chief American envoy and to give a lift to the diplomatic stalemate on Syria. Mr. Kerry, who took office this month, is traveling to Britain, Germany, France, Italy, Turkey, Egypt, Saudi Arabia, the United Arab Emirates and Qatar over 11 days.

Even before his trip was formally announced, Mr. Kerry raised expectations by saying he had new ideas on how to change Mr. Assad’s calculations that he could remain in power.

Mr. Kerry has not publicly explained the proposals, but they appear to include marshaling support from Russia, which has been providing arms and financial help to Mr. Assad. Toward that end, Mr. Kerry plans to meet in Berlin on Wednesday with Sergey V. Lavrov, Russia’s foreign minister.

The meeting with the Syrian opposition is to be hosted by Italy. Last week, the European Union agreed to extend its embargo on weapons shipments to Syria for another three months, a move that precludes European arms shipments to the opposition.

But the European Union did agree to a British proposal that nonlethal assistance be expanded. As a result, body armor, night-vision goggles, armored vehicles and other equipment can be sent to armed opposition groups in Syria, an American official said.

So far, the Obama administration has not gone that far in its support. While the United States provides nonlethal assistance like computers and radios to the opposition, it has not been willing to provide nonlethal aid to armed factions within Syria, an approach that experts say has limited its influence with these groups.

State Department officials traveling with Mr. Kerry declined to discuss whether the United States would soon be prepared to take that step.

President Obama rebuffed a proposal last year from the State Department, the Pentagon and the C.I.A. that the United States arm and train a cadre of opposition fighters.

With the violence escalating, Aleppo under attack by Scud missiles and members of a quarrelsome Syrian opposition challenging the value of the Rome meeting — which was supposed to be a highlight of Mr. Kerry’s trip — the State Department issued a statement on Saturday evening that condemned the rocket attacks “in the strongest possible terms” and prodded the Syrian opposition to attend the session.

The statement continued, “We look forward to meeting soon with the leadership of the legitimate representative of the Syrian people, the Syrian Opposition Coalition, to discuss how the United States and other friends of the Syrian people can do more to help the Syrian people achieve the political transition that they demand and that they deserve.”

Read More..

Channing Tatum & Jenna Dewan-Tatum Show Off Baby Bump at Oscars

By Maggie Coughlan

02/24/2013 at 06:45 PM EST

Channing Tatum and Jenna Dewan-Tatum

Jason Merritt/Getty

Who is your bump wearing?

Parents-to-be Channing Tatum and Jenna Dewan-Tatum brought a very special guest to Sunday night's 85th Annual Academy Awards – wearing a black lace, backless dress, Dewan-Tatum, 32, showed off her new curves, while husband Tatum revealed where their baby will be born.

"I'm walking the carpet, trying to keep it together tonight but we're good!" a radiant Dewan-Tatum told Ryan Seacrest on the red carpet Sunday night.

When asked by Seacrest if the couple had any plans to slow down for some "family time," Tatum, 32, replied: "We're gonna actually have the baby in London while I'm shooting so there will be no downtime whatsoever after that."

Tatum – who was named PEOPLE's 2012 Sexiest Man Alive – recently told PEOPLE that he's doing his homework before the baby arrives.

"I have never changed a diaper before, so I may need some help learning," the actor said at the time. "I don't have friends who have kids, so it's going to be an interesting experience to learn how to change a diaper."

The couple's first child is due this summer.

Read More..

FDA approves new targeted breast cancer drug

WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.

The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.

Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.

"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."

Cobleigh helped conduct the key studies of the drug at the Chicago facility.

The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.

The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.

Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.

FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.

Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.

FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer

Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.

Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.

Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.

Read More..

Asian shares edge higher, yen falls on BOJ report

TOKYO (Reuters) - Asian shares edged higher on Monday, with investors still picking up shares battered by last week's steep plunge, while the yen fell to fresh lows on news a reflationary advocate could head the Bank of Japan next month.

The news Japan's government is likely to nominate Asian Development Bank President Haruhiko Kuroda, an advocate of aggressive monetary easing, as its next central bank governor, is set to be a major factor in financial markets this week.

Markets are pondering whether Italy's weekend elections will produce a stable government, and the implications of that for euro zone cohesion, while Moody's credit downgrade on Britain will play on confidence in the pound and government bonds.

Investors also await testimony on Tuesday from Fed Chairman Ben Bernanke for further clues of when the Fed may slow or stop buying bonds. Financial markets were rattled last week after minutes of the Fed's January meeting suggested some Fed officials were mulling scaling back its strong monetary stimulus earlier than expected.

The MSCI's broadest index of Asia-Pacific shares outside Japan <.miapj0000pus> was up 0.1 percent, pulled higher by Australian shares <.axjo> which gained 0.6 percent on reassuring comments from U.S. Federal Reserve officials on the bank's current stimulus program, which has helped underpin risk sentiment globally.

South Korean shares <.ks11> opened up 0.2 percent, with the nation's new leader, who has shown willingness to talk down the won, being sworn in on Monday.

Tokyo's Nikkei stock average <.n225> opened 1.6 percent higher. <.t/>

Early on Monday, the yen touched its lowest since May 2010 of 94.61 yen against the dollar, while the euro rose to a high of 124.83 yen, still off its 34-month peak of 127.71 set early this month.

The Nikkei newspaper reported the Japanese government is likely to nominate Haruhiko Kuroda and Kikuo Iwata, both vocal advocates of aggressive monetary expansion, as BOJ governor and deputy governor.

The dollar fell sharply to below 93 yen last week on media reports that Toshiro Muto, a former financial bureaucrat perceived as less willing to take unconventional steps, was the frontrunner candidate for the top BOJ job.

"The dollar's move this morning is merely a rebound from disappointment on Muto last week. I don't think this topic will be enough to hoist the dollar above 95 yen," said Hiroshi Maeba, head of FX trading Japan at UBS in Tokyo. "No matter who is elected at the BOJ, it will not affect the longer-term trend of a weak yen," he said.

Speculation over the BOJ has been a key factor driving the yen lower recently due to anticipation for strong reflationary measures, but other fundamental factors such as Japan's deteriorating trade balances and signs of firmer U.S. growth also supported a weakening yen trend.

Abe told Americans on Friday "I am back and so is Japan" and vowed to get the world's third biggest economy growing again.

Investors remained cautious before the full official results of Italy's elections come out on Tuesday, worried a potential political stalemate could impede Rome's progress on fiscal reforms.

The euro was up 0.1 percent to $1.3192, off Friday's six-week low of $1.31445.

Sterling fell to a 31-month low of $1.5073 early on Monday and a record low against the New Zealand dollar at NZ$1.8025 following Friday's one-notch downgrade of Britain's prized triple-A sovereign rating by Moody's.

Investors will also seek signs of recovery from the flash estimate of China's manufacturing PMI from HSBC/Markit due later in the session.

Wall Street ended higher on Friday, boosted strong earnings from Dow component Hewlett-Packard , but the benchmark Standard & Poor's Index <.spx> posted its first weekly decline of the year. European shares rose on Friday after data showed German business morale surged at its fastest pace in over two years in February.

Hedge funds and other big speculators cut their bullish bets on U.S. commodities by nearly $13 billion, the most in about 10 months, in the week to February 19 to $69 billion, just before oil and metals prices tumbled last week on rumors a commodities fund was dumping positions, trade data showed on Friday.

U.S. crude was up 0.1 percent to $93.26 a barrel.

(Editing by Eric Meijer)

Read More..

Syrian Flood Into Lebanon Stirs Fear of Looming Disaster

QAA, Lebanon — Quietly but inexorably, a human tide has crept into Lebanon, Syria’s smallest and most vulnerable neighbor.

As Syrians fleeing civil war pour over the border, the village priest here, Elian Nasrallah, trudges through muddy fields to deliver blankets. His family runs a medical clinic for refugees. When Christian villagers fret about the flood of Sunni Muslims, he replies that welcoming them is “the real Christianity.”

But the priest and his parishioners cannot keep up. The United Nations counts more than 305,000 Syrian refugees in Lebanon, but local officials and aid workers say the actual number is about 400,000, saturating this country of four million.

The Lebanese government — by design — has largely left them to fend for themselves. Deeply divided over Syria, haunted by memories of an explosive refugee crisis a generation ago, it has mostly ignored the problem, dumping it on overwhelmed communities like Qaa.

So far, Lebanon’s delicate balance has persevered, but there is a growing sense of emergency.

Sectarian tensions are rising. Fugitive Syrian rebels in border villages have clashed with Lebanese soldiers. The government’s anemic response has delayed international aid. Local volunteers are running out of cash and patience.

And the battle for Damascus, Syria’s capital, has barely begun. Should fighting overwhelm that religiously and politically mixed city of 2.5 million a half-hour drive from Lebanon, the Lebanese fear a cataclysm that could sweep away their tenuous calm.

“There is a limit to what the country can handle,” said Nadim Shubassi, mayor of Saidnayel, a Sunni town now packed with Syrians. “Maybe we have reached this limit now.”

Lebanon’s refugee crisis does not match the familiar image of vast, centralized tent camps and armies of foreign aid organizations. It is nowhere, and everywhere. Displaced Syrians seem to fill every nook and cranny: half-finished cinder block houses, stables, crowded apartments.

It is easy to miss them, until a second glance. Drying laundry peeks from construction sites. Bedsheets hang in shop windows, concealing stark living spaces. Daffodil sellers, shoeshine men, women and children begging in Beirut — all incant, “Min Suria.” From Syria.

At first, most refugees — mainly Sunnis, like most of the rebels fighting Syria’s government — headed for friendly Sunni areas. Now, those communities are swamped and resentful, and Syrians are spreading to places where they fit less comfortably, from Christian mountain villages to the Mediterranean city of Tyre in the southern Shiite Muslim heartland.

They are moving, with some trepidation, into Qaa, in the northern Bekaa Valley, the territory of the powerful Shiite militia Hezbollah, which is allied with Syria’s government and, to many refugees, just as fearsome.

As they flee increasingly sectarian killing, Syrians layer their fears onto those of a country deeply scarred by its own generation-long sectarian civil war. They are testing, yet also relying on, the fragile yet flexible balance that has endured here, punctured by occasional fighting, since Lebanon’s war ended 22 years ago.

In Baalbek, a Hezbollah stronghold where a poster of the Syrian president, Bashar al-Assad, grins down on a busy street, refugees turn to Sawa, a community group that views helping them as embodying its nonsectarian mission. Still, they rattle Abbas Othman, a Sawa member.

“We are worried they will bring their civil war here,” he said.

One recent evening in Qaa, Mr. Nasrallah, the priest, stood outside a burlap shack that sheltering a Syrian family of 12. They clamored around him; they had eaten only potatoes that day. Cold crept in as a blue dusk fell. One man implored, “You are responsible for us!”

The priest threw up his hands.

“It’s wartime,” he said. “Is the government doing its job or not?”

Lebanese decision-makers wanted it this way, at first. A year ago, just 5,000 Syrians had fled here, and Hezbollah, Lebanon’s most powerful political party, denied any sense of crisis.

Reporting was contributed by Hwaida Saad, Hania Mourtada, Ben Solomon and Lynsey Addario.

Read More..

Predict the Oscar Winners!

• Facebook


• Tweet

• Facebook


• Tweet

Cast your vote for who will be the night's big winners Click here to download a printable ballot.

Click here to download a printable ballot.

Polls
completed:

Read More..

FDA approves new targeted breast cancer drug

WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.

The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.

Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.

"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."

Cobleigh helped conduct the key studies of the drug at the Chicago facility.

The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.

The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.

Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.

FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.

Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.

FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer

Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.

Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.

Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.

Read More..